Crenolanib is an investigational pharmaceutical compound that functions as a tyrosine kinase inhibitor. It is being studied in clinical trials for various cancer types, including acute myeloid leukemia, gastrointestinal stromal tumor, and glioma.
콘텐츠 범위: 이 페이지의 정보는 화학물질 식별 및 산업 공급·연구개발·제조 맥락을 대상으로 합니다. 치료 효능 주장, 의료 조언 또는 의약품 사용 지침에 해당하지 않습니다.
이 화합물을 구매하거나 공급하시겠습니까?
재고를 등록하거나 구매 요청을 게시하세요
CAS 670220-88-9
Neratinib
tyrosine kinase inhibitor
XL-228
tyrosine kinase inhibitor
N-[3-[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
tyrosine kinase inhibitor
Repotrectinib
tyrosine kinase inhibitor
3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
active pharmaceutical ingredient
Metirosine, (R)-
active pharmaceutical ingredient
Metirosine
catecholamine synthesis inhibitor
DPPG-Na
active pharmaceutical ingredient
1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
DYNHJHQFHQTFTP-UHFFFAOYSA-N
CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4